PharmaLogic to acquire Lantheus CDMO business and Springfield facility

PharmaLogic Holdings Corp. has agreed to buy the contract development and manufacturing business, or CDMO, and the Springfield, New Jersey, facility from Lantheus Holdings, Inc.¹ The announced transaction brings an existing radiopharmaceutical manufacturing operation into PharmaLogic’s business, rather than describing a newly built site.¹ The agreement’s stated scope includes both the CDMO operation and the Springfield property, while the parties have not released its financial terms.¹ That absence of a disclosed price means the announcement provides no purchase amount with which to measure the deal’s financial size.¹ The principal stated change is therefore operational: PharmaLogic would add the site and business to its radiopharmaceutical manufacturing capacity in the United States.¹

The Springfield location is described as a modern radiopharmaceutical production site with an established record in theranostics, research, and clinical development.¹ Theranostics is one of the areas specifically associated with the facility, alongside research and clinical work; the announcement does not provide output volumes or a count of projects.¹ The description gives a picture of the kinds of work the facility has supported, but not a quantified measure of its capacity or past production.¹ PharmaLogic says the addition will expand its ability to make radiopharmaceutical therapeutics within the United States.¹ The release does not attach a numerical estimate to that expansion, so the size of the added capacity cannot be compared with existing production from the information provided.¹

When the transaction is completed, the Springfield employees are expected to become part of Agilera, PharmaLogic’s therapeutic CDMO business.¹ That arrangement identifies the destination for the team within PharmaLogic, but the announcement does not specify how many employees are affected or whether their roles will change.¹ The parties will continue running their businesses separately until the acquisition closes.¹ The intended transfer of the team is therefore tied to completion rather than an immediate operational combination.¹ Completion depends on applicable regulatory review and other customary closing conditions, and no closing date is given in the stated terms.¹

Alongside the acquisition, the parties have included a long-term supply arrangement for lutetium Lu 177 dotatate.¹ Under that agreement, Agilera is to manufacture the medicine for Lantheus.¹ The supply commitment connects the transferred manufacturing operation with an ongoing product-supply role for the seller.¹ The announcement does not state the agreement’s duration in years, the quantities to be supplied, or when production under it begins.¹ Those details are distinct from the disclosed fact that the arrangement is long term and names Agilera as manufacturer and Lantheus as recipient.¹

Agilera is described as having more than 15 years of experience helping develop radioligand therapies and support their commercial launches.¹ That figure refers to the franchise’s experience, not the age of the Springfield site or the length of the new supply agreement.¹ Agilera also currently supplies an alpha therapy to more than 30 countries.¹ The country count describes the reach of that existing supply, not the number of countries covered by the Springfield acquisition or the lutetium Lu 177 dotatate agreement.¹ The release gives no country-by-country breakdown or volume for the alpha therapy, so the figure indicates geographic reach rather than a measured quantity of medicine.¹

PharmaLogic says the Springfield addition makes it the first therapeutic CDMO to offer a transatlantic platform for radioligand therapies.¹ This is a claim about the platform PharmaLogic says it will offer with the facility, not a separate quantified measure of production or market share.¹ The company also describes itself as North America’s only independent CDMO of scale focused exclusively on radiopharmaceuticals.¹ Its stated network comprises more than 45 facilities spread across the United States, Puerto Rico, Canada, and Norway.¹ The count refers to PharmaLogic’s existing facilities across those locations, while Springfield is the site covered by the announced purchase.¹

PharmaLogic further says it is the only cGMP-compliant CDMO currently making and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries.¹ That country figure concerns the distribution reach of a commercial therapeutic and is separate from Agilera’s stated supply of an alpha therapy to more than 30 countries.¹ The release does not identify the countries in either count, or say whether the two sets of destinations overlap.¹ These descriptions provide context for PharmaLogic’s current operations, but they do not quantify how much the new facility will add to its network’s output.¹ The transaction’s stated U.S. capacity expansion and the company’s existing international reach are therefore different measures of its business.¹

PharmaLogic chief executive Etienne Montagut said the purchase would strengthen Agilera’s capabilities and increase capacity in the United States.¹ Lantheus executive chairperson and chief executive Mary Anne Heino described PharmaLogic as a suitable long-term owner for the CDMO operation and Springfield site.¹ Their comments set out each company’s stated rationale: PharmaLogic emphasized its capabilities and domestic capacity, while Lantheus emphasized the future ownership of the business and facility.¹ The transaction remains conditional on regulatory review and other customary requirements, and both companies are to operate independently until closing.¹ The announcement does not provide a regulatory timetable or describe the specific review process.¹

Advisers were named for both sides of the transaction.¹ Leerink Partners advised PharmaLogic on financial matters, and Goodwin Procter LLP served as its legal adviser.¹ For Lantheus, Solomon Partners Securities LLC was the financial adviser and Covington & Burling LLP provided legal advice.¹ Lantheus is described as a radiopharmaceutical-focused company with 70 years of experience and offices in multiple countries.¹ The 70-year figure describes Lantheus’s experience, while the release gives no exact number for its offices or their locations.¹